Table 1 Baseline characteristics of hCCA patients in the training and testing sets.
Variables | Training set (n = 237) | Testing group (n = 103) | P-value |
|---|---|---|---|
Demography | |||
Gender (%) | |||
Female | 125 (53) | 51 (50) | 0.668 |
Male | 112 (47) | 52 (50) | |
Age, (years) (%) | |||
<55 | 49 (21) | 24 (23) | 0.691 |
≥55 | 188 (79) | 79 (77) | |
Clinical feature | |||
Abdominal pain (%) | |||
No | 140 (59) | 62 (60) | 0.941 |
Yes | 97 (41) | 41 (40) | |
Bloating (%) | |||
No | 170 (72) | 77 (75) | 0.658 |
Yes | 67 (28) | 26 (25) | |
Jaundice (%) | |||
No | 41 (17) | 12 (12) | 0.247 |
Yes | 196 (83) | 91 (88) | |
Child-Pugh (%) | |||
A | 42 (18) | 13 (13) | 0.078 |
B | 191 (81) | 84 (82) | |
C | 4 (2) | 6 (6) | |
Laboratory | |||
TBIL, (µmol/L) (%) | |||
<100 | 89 (38) | 33 (32) | 0.395 |
≥100 | 148 (62) | 70 (68) | |
CA19-9, (u/ml) (%) | |||
<100 | 77 (32) | 32 (31) | 0.895 |
≥100 | 160 (68) | 71 (69) | |
Surgery | |||
PBD (%) | |||
No | 151 (64) | 70 (68) | 0.528 |
ENBD or PTCD | 86 (36) | 33 (32) | |
Bismuth–Corlette (%) | |||
I | 49 (21) | 20 (19) | 0.197 |
II | 38 (16) | 15 (15) | |
IIIa | 60 (25) | 20 (19) | |
IIIb | 52 (22) | 20 (19) | |
V | 38 (16) | 28 (27) | |
Surgical procedure (%) | |||
Bile duct resection | 85 (36) | 39 (38) | 0.71 |
Perihilar hepatectomy | 12 (5) | 4 (4) | |
Right hemihepatectomy | 70 (30) | 25 (24) | |
Left hemihepatectomy | 70 (30) | 35 (34) | |
Vascular invasion (%) | |||
No | 205 (86) | 92 (89) | 0.356 |
Portal vein invasion | 16 (7) | 8 (8) | |
Hepatic artery invasion | 16 (7) | 3 (3) | |
Vascular resection (%) | |||
No | 210 (89) | 92 (89) | 0.53 |
Portal vein | 23 (10) | 11 (11) | |
Hepatic artery | 4 (2) | 0 (0) | |
Tumor size, (cm) (%) | |||
<1.5 | 65 (27) | 22 (21) | 0.389 |
1.5-3 | 93 (39) | 40 (39) | |
>3 | 79 (33) | 41 (40) | |
TLNC (%) | |||
≤6 | 109 (46) | 50 (49) | 0.536 |
7–12 | 100 (42) | 45 (44) | |
≥13 | 28 (12) | 8 (8) | |
Chemotherapy (%) | |||
No | 193 (81) | 88 (85) | 0.459 |
Yes | 44 (19) | 15 (15) | |
Positive margin (%) | |||
No | 177 (75) | 81 (79) | 0.518 |
Yes | 60 (25) | 22 (21) | |
Clavien-Dindo (%) | |||
No | 43 (18) | 12 (12) | 0.06 |
I | 82 (35) | 44 (43) | |
II | 72 (30) | 38 (37) | |
≥III | 40 (17) | 9 (9) | |
Pathology and clinical stages | |||
Differentiation (%) | |||
Well | 35 (15) | 18 (17) | 0.747 |
Moderate | 129 (54) | 52 (50) | |
Poorly | 73 (31) | 33 (32) | |
Liver invasion (%) | |||
No | 117 (49) | 53 (51) | 0.813 |
Yes | 120 (51) | 50 (49) | |
Perineural invasion (%) | |||
No | 138 (58) | 68 (66) | 0.219 |
Yes | 99 (42) | 35 (34) | |
T stage (%) | |||
T1 | 32 (14) | 15 (15) | 0.429 |
T2a | 57 (24) | 22 (21) | |
T2b | 64 (27) | 34 (33) | |
T3 | 53 (22) | 25 (24) | |
T4 | 31 (13) | 7 (7) | |
N stage (%) | |||
N0 | 167 (70) | 69 (67) | 0.576 |
N1 | 55 (23) | 29 (28) | |
N2 | 15 (6) | 5 (5) | |
TNM stage (%) | |||
I/II | 120 (51) | 47 (46) | 0.506 |
IIIA/IIIB/IIIC | 103 (43) | 50 (49) | |
IVA | 14 (6) | 6 (5) | |
Status (%) | |||
Survival | 43 (18) | 18 (17) | 1 |
Death | 194 (82) | 85 (83) | |
Median time, (month) (Q1,Q3) | 21.7 (10.9, 36.9) | 22.1 (10.4, 38.0) | 0.48 |
